DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 200 filers reported holding DENALI THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.71 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,075,462 | +381.0% | 36,444 | +275.5% | 0.01% | +400.0% |
| Q1 2023 | $223,603 | -62.6% | 9,705 | -54.8% | 0.00% | -66.7% |
| Q4 2022 | $597,553 | -54.0% | 21,487 | -49.3% | 0.00% | -57.1% |
| Q3 2022 | $1,300,000 | -8.1% | 42,356 | -11.9% | 0.01% | 0.0% |
| Q2 2022 | $1,414,000 | +17.5% | 48,058 | +28.5% | 0.01% | 0.0% |
| Q1 2022 | $1,203,000 | +93.4% | 37,389 | +168.2% | 0.01% | +133.3% |
| Q4 2021 | $622,000 | -31.6% | 13,941 | -22.6% | 0.00% | -50.0% |
| Q3 2021 | $909,000 | -43.0% | 18,016 | -35.6% | 0.01% | -50.0% |
| Q1 2021 | $1,596,000 | +35.4% | 27,958 | +98.6% | 0.01% | +20.0% |
| Q4 2020 | $1,179,000 | -72.5% | 14,074 | -88.3% | 0.01% | -72.2% |
| Q3 2020 | $4,295,000 | +1604.4% | 119,879 | +1052.4% | 0.04% | +1100.0% |
| Q2 2020 | $252,000 | – | 10,403 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $298,165,000 | 48.02% |
| Bratton Capital Management, L.P. | 953,035 | $14,600,000 | 28.53% |
| Flagship Pioneering Inc. | 8,005,747 | $122,648,000 | 6.71% |
| Casdin Capital, LLC | 650,000 | $9,958,000,000 | 1.03% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $67,568,000 | 0.50% |
| MARK ASSET MANAGEMENT LP | 68,864 | $1,055,000 | 0.26% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 22,507 | $345,000 | 0.26% |
| Artal Group S.A. | 400,000 | $6,128,000 | 0.25% |
| PIER 88 INVESTMENT PARTNERS LLC | 40,610 | $622,000 | 0.24% |
| HAMILTON LANE ADVISORS LLC | 30,948 | $474,000 | 0.20% |